Modified Consent May Aid Psychedelic Trials
-
By
January 8, 2025
-
3 min
-
1
High percentages of participants in psychedelic trials were able to correctly identify receiving active treatment vs placebo, raising concerns about expectancy effects and placebo responses.
-
2
The study proposes modifications to informed consent procedures to improve scientific validity while maintaining ethical standards.
-
3
There is a critical need for standardized best practices for measuring masking success in psychedelic research.
-
4
Ethical compliance requires clear disclosure and management of significant risks.
-
5
FDA's breakthrough therapy designations to psychedelic treatments have fueled optimism about their therapeutic potential.
-
A recent study from the University of California, San Francisco and the San Francisco Veterans Administration Medical Center has highlighted the challenge of unmasking in psychedelic drug trials. The study proposes modifications to informed consent procedures to improve scientific validity while maintaining ethical standards, as high percentages of participants were able to correctly identify receiving active treatment versus placebo. The analysis underscores the need for standardized best practices for measuring the success of masking and managing ethical risks in future psychedelic research.
-
1
High percentages of participants in psychedelic trials were able to correctly identify receiving active treatment vs placebo, raising concerns about expectancy effects and placebo responses.
-
2
The study proposes modifications to informed consent procedures to improve scientific validity while maintaining ethical standards.
-
3
There is a critical need for standardized best practices for measuring masking success in psychedelic research.
-
4
Ethical compliance requires clear disclosure and management of significant risks.
-
5
FDA's breakthrough therapy designations to psychedelic treatments have fueled optimism about their therapeutic potential.
Listen Tab content
